Stockscreener 앱 받기
69.42
0.30%
0.354
전일 마감가:
$69.07
열려 있는:
$70.24
하루 거래량:
2.18M
Relative Volume:
0.40
시가총액:
$26.80B
수익:
$4.82B
순이익/손실:
$930.40M
주가수익비율:
29.69
EPS:
2.3381
순현금흐름:
$1.43B
1주 성능:
-5.30%
1개월 성능:
-3.91%
6개월 성능:
+3.62%
1년 성능:
-13.23%
1일 변동 폭
$68.91
$70.27
1주일 범위
$68.55
$74.26
52주 변동 폭
$54.11
$89.98
덱스컴 Stock (DXCM) Company Profile
명칭
Dexcom Inc
전화
(858) 200-0200
주소
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
69.44 | 27.96B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
90.40 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
308.51 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.28 | 101.56B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.98 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.61 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
덱스컴 Stock (DXCM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2026-01-12 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-12-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | 개시 | Evercore ISI | In-line |
| 2025-10-21 | 재개 | Stifel | Buy |
| 2025-09-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-21 | 개시 | Argus | Buy |
| 2025-06-16 | 개시 | Truist | Buy |
| 2025-05-30 | 개시 | Goldman | Buy |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-03 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 개시 | Redburn Atlantic | Neutral |
| 2024-03-12 | 개시 | RBC Capital Mkts | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-04-17 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 개시 | UBS | Buy |
| 2023-01-26 | 개시 | Wolfe Research | Outperform |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-15 | 개시 | Bernstein | Outperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-01-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-28 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2021-01-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-10-02 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 재확인 | Piper Sandler | Overweight |
| 2020-05-14 | 개시 | Wells Fargo | Equal Weight |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-11-07 | 재확인 | Canaccord Genuity | Buy |
| 2019-11-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-10-23 | 개시 | Stifel | Buy |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-19 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-09-12 | 업그레이드 | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 재확인 | Canaccord Genuity | Buy |
| 2018-07-02 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
| 2018-05-03 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-04 | 개시 | Goldman | Sell |
| 2018-04-04 | 개시 | Guggenheim | Neutral |
| 2018-03-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | 다운그레이드 | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 재확인 | Wedbush | Outperform |
모두보기
덱스컴 주식(DXCM)의 최신 뉴스
Dexcom receives pediatric clearance for Stelo biosensor - Investing.com
Dexcom Further Advances Vision of Glucose Biosensing for All - Dexcom Investor Relations
Dexcom expands Stelo to children, with July app launch and UK plans - Stock Titan
Deutsche Bank initiates DexCom stock with buy rating on CGM growth - Investing.com
Benchmark reiterates Dexcom stock rating on new sensor launch - Investing.com
Deutsche Bank Initiates Coverage on DexCom With Buy Rating, $86 Price Target - marketscreener.com
A Look at DexCom Inc (DXCM) After 4.7% Decline -- GF Value $103. - GuruFocus
Dexcom G7 from Dexcom Inc.30-minute warmup and more discreet wear - AD HOC NEWS
Dexcom alerts users after stolen G7 sensors allegedly sold by unauthorized distributor - Class Action Lawsuits
Piper Sandler Raises its Price Target on DexCom (DXCM) - Insider Monkey
DexCom, Inc. (DXCM) Stock Analysis: Navigating A 17.58% Upside In The Healthcare Sector - DirectorsTalk Interviews
Dexcom Stockweekly outlook with earnings ahead - AD HOC NEWS
Redefining CGM for people with type 2 diabetes: Dexcom announces Dexcom Flex in Germany - MSN
3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound - Investing.com
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
DexCom (DXCM) EVP Michael Jon Brown sells 1,700 shares in pre-set 10b5-1 trade - Stock Titan
Dexcom (NASDAQ: DXCM) director’s family trust sells 4,000 shares under 10b5-1 plan - Stock Titan
Dexcom Inc (DXCM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dexcom Inc (DXCM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dexcom Inc (DXCM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dexcom Inc (DXCM) Institutional Confidence - TradingKey
Dexcom Inc (DXCM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Dexcom Inc (DXCM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dexcom Inc (DXCM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dexcom Inc (DXCM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
DexCom Inc. stock outperforms competitors on strong trading day - MSN
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
[144] DEXCOM INC SEC Filing - Stock Titan
DexCom Inc. stock underperforms Monday when compared to competitors - MarketWatch
Michael Brown files sale notice — Michael Brown (NASDAQ: DXCM) seeks to sell 1,700 shares - Stock Titan
Dexcom Scores Pediatric Expansion For OTC Stelo Glucose Monitor - Benzinga
In a first, Dexcom’s OTC glucose sensor is cleared for kids - MedTech Dive
DexCom, Inc. (DXCM) Stock Analysis: Exploring a 13% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
DexCom’s quarterly earnings preview: What you need to know - MSN
How G7 CONNECT Trial Results at DexCom (DXCM) Have Changed Its Investment Story - Sahm
Dexcom reports positive CONNECT data for non-insulin diabetes - MSN
DexCom (DXCM) Launches First Over-the-Counter Glucose Monitor fo - GuruFocus
Dexcom (DXCM) Launches First OTC Glucose Monitor for Children - GuruFocus
FDA clears first over-the-counter glucose monitor for children - marketscreener.com
Here's why you should retain DexCom stock in your portfolio - MSN
DexCom Expands Beyond CGMs With CONNECT Results AI Apps And Nutrisense Deal - Yahoo Finance
Lyell Wealth Management LP Cuts Holdings in DexCom, Inc. $DXCM - MarketBeat
Vestal Point Capital, LP's DexCom Inc(DXCM) Holding History - GuruFocus
A Watch on DexCom: Expanding Access and Innovation Drive the Next Chapter of CGM Leadership - Kalkine
3 Reasons Investors Love DexCom (DXCM) - Yahoo Finance
Pharmsource says it was unaware Dexcom sensors it bought were slated for destruction - Reuters
Goodman Advisory Group LLC Invests $1.29 Million in DexCom, Inc. $DXCM - MarketBeat
DexCom Says Diabetes Tech Issue Isn't Investor Fraud - Law360
TD Cowen Remains a Buy on Dexcom (DXCM) - The Globe and Mail
Dexcom Inc. stock (US2521311074): TD Cowen lifts target after strong Q1 momentum - AD HOC NEWS
TD Cowen raises DexCom stock price target to $95 on data - Investing.com UK
덱스컴 (DXCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
덱스컴 주식 (DXCM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| FOLETTA MARK G | Director |
Jun 15 '26 |
Sale |
74.13 |
4,000 |
296,540 |
52,852 |
1.26%
1.40%
자본화:
|
볼륨(24시간):